These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28107795)

  • 21. New and Emerging Treatments for Cystic Fibrosis.
    Barry PJ; Jones AM
    Drugs; 2015 Jul; 75(11):1165-75. PubMed ID: 26091951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
    Goa KL; Lamb H
    Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhaled medications in cystic fibrosis beyond antibiotics.
    Sepe A; Villella VR; Cimbalo C; Castaldo A; Nunziata F; Corcione A; Bona G; Maiuri L; Raia V
    Minerva Pediatr; 2019 Aug; 71(4):371-375. PubMed ID: 30761821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cystic fibrosis 2019: Year in review.
    Doull I
    Paediatr Respir Rev; 2020 Sep; 35():95-98. PubMed ID: 32359945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dornase alfa (Pulmozyme).
    Wagener JS; Kupfer O
    Curr Opin Pulm Med; 2012 Nov; 18(6):609-14. PubMed ID: 22990660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence to the 2007 cystic fibrosis pulmonary guidelines: a national survey of CF care centers.
    Glauser TA; Nevins PH; Williamson JC; Abdolrasulnia M; Salinas GD; Zhang J; Debonnett L; Riekert KA
    Pediatr Pulmonol; 2012 May; 47(5):434-40. PubMed ID: 22495970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung clearance index response in patients with CF with class III CFTR mutations.
    Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F
    Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of pulmonary clearance medications in the acutely ill patient.
    Papacostas MF; Luckett P; Hupp S
    Expert Rev Respir Med; 2017 Oct; 11(10):815-826. PubMed ID: 28780895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients.
    Amaral MD
    J Intern Med; 2015 Feb; 277(2):155-166. PubMed ID: 25266997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
    Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
    Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care?
    Bilton D; Stanford G
    Curr Opin Pulm Med; 2014 Nov; 20(6):601-6. PubMed ID: 25221855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tezacaftor for the treatment of cystic fibrosis.
    Sala MA; Jain M
    Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
    Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
    Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.
    Suthoff ED; Bonafede M; Limone B; O'Callaghan L; Sawicki GS; Wagener JS
    J Med Econ; 2016 Sep; 19(9):845-51. PubMed ID: 27074519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting.
    Hubert D; Dehillotte C; Munck A; David V; Baek J; Mely L; Dominique S; Ramel S; Danner Boucher I; Lefeuvre S; Reynaud Q; Colomb-Jung V; Bakouboula P; Lemonnier L
    J Cyst Fibros; 2018 Jan; 17(1):89-95. PubMed ID: 28711222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis.
    Cheng PC; Alexiou S; Rubenstein RC
    Expert Rev Respir Med; 2019 May; 13(5):417-423. PubMed ID: 30929526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.